| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
5,000,000 |
| Market
Cap: |
7.25(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.1 - $13.42 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Onconova Therapeutics is a biopharmaceutical company focused on discovering and developing small molecule product candidates primarily to treat cancer. Co. has three clinical-stage product candidates and preclinical programs. Substantially all of Co.'s effort is focused on its primary product candidate, rigosertib, which has been tested in an intravenous formulation as a single agent for patients with higher-risk myelodysplastic syndromes (MDS), and an oral formulation as a single agent in lower risk MDS or in combination with azacitidine for patients with higher-risk MDS. Co.'s other product candidate, Briciclib, is a small molecule targeting an intracellular regulatory protein, Cyclin D1.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2025-04-06 |
2025-01-03 |
2024-07-05 |
2023-07-06 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Savchuk Nikolay |
Chief Operating Officer |
• – • |
2025-04-02 |
4 |
D |
$0.00 |
$0 |
D/D |
(605,531) |
0 |
|
- |
|
| Cautreels Werner |
Chief Executive Officer |
• • – |
2025-02-18 |
4 |
OE |
$0.01 |
$963 |
D/D |
96,348 |
104,348 |
|
- |
|
| Orbimed Capital Gp Viii Llc |
10% Owner |
– – • |
2024-09-16 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
602,000 |
|
-17% |
|
| Guerin Mark Patrick |
CFO |
• – – |
2024-06-18 |
4 |
D |
$0.47 |
$1,044 |
D/D |
(2,221) |
39,255 |
|
- |
|
| Guerin Mark Patrick |
CFO |
• – – |
2024-06-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,500 |
41,476 |
|
- |
|
| Viriom, Inc. |
|
– – • |
2024-04-03 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,645,100 |
|
-60% |
|
| Savchuk Nikolay |
Chief Operating Officer |
• • – |
2024-04-01 |
4/A |
A |
$0.00 |
$0 |
D/D |
67,500 |
134,187 |
|
- |
|
| Dukes Iain D. |
Executive Chairman |
• • – |
2024-04-01 |
4/A |
A |
$0.00 |
$0 |
D/D |
67,500 |
134,187 |
|
- |
|
| Orbimed Capital Gp Viii Llc |
|
– – – |
2024-04-01 |
3/A |
IO |
$0.00 |
$0 |
I/I |
0 |
1,045,261 |
|
- |
|
| Tpav, Llc |
|
– – • |
2024-04-01 |
3/A |
IO |
$0.00 |
$0 |
D/D |
0 |
1,222,738 |
|
- |
|
| Orbimed Capital Gp Viii Llc |
|
– – • |
2024-04-01 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
885,532 |
|
-63% |
|
| Tpav, Llc |
|
– – • |
2024-04-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
885,532 |
|
-63% |
|
| Pauza Charles David |
Chief Science Officer Virology |
• • – |
2024-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
97,500 |
97,500 |
|
- |
|
| Redfield Robert |
Acting Chief Medical Officer |
• • – |
2024-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
97,500 |
97,500 |
|
- |
|
| Savchuk Nikolay |
Chief Operating Officer |
• • – |
2024-04-01 |
4 |
A |
$0.00 |
$0 |
I/I |
2,530,632 |
1,645,100 |
|
- |
|
| Savchuk Nikolay |
Chief Operating Officer |
• • – |
2024-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
134,237 |
134,187 |
|
- |
|
| Dukes Iain D. |
Executive Chairman |
• • – |
2024-04-01 |
4 |
A |
$0.00 |
$0 |
I/I |
1,645,100 |
1,645,100 |
|
- |
|
| Dukes Iain D. |
Executive Chairman |
• • – |
2024-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
134,237 |
134,187 |
|
- |
|
| Cautreels Werner |
Chief Executive Officer |
• • – |
2024-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
200,000 |
200,000 |
|
- |
|
| Guerin Mark Patrick |
CFO AND COO |
• – – |
2024-03-14 |
4 |
D |
$0.90 |
$2,332 |
D/D |
(2,591) |
35,976 |
|
- |
|
| Fruchtman Steven M |
PRESIDENT, CHIEF EXECUTIVE OFF |
• • – |
2024-03-14 |
4 |
D |
$0.90 |
$7,854 |
D/D |
(8,727) |
74,792 |
|
- |
|
| Guerin Mark Patrick |
CFO AND COO |
• – – |
2024-03-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,666 |
38,567 |
|
- |
|
| Fruchtman Steven M |
PRESIDENT, CHIEF EXECUTIVE OFF |
• • – |
2024-03-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
23,111 |
83,519 |
|
- |
|
| Guerin Mark Patrick |
CFO AND COO |
• – – |
2024-02-07 |
4 |
D |
$0.67 |
$1,637 |
D/D |
(2,443) |
29,901 |
|
- |
|
| Guerin Mark Patrick |
CFO AND COO |
• – – |
2024-02-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,900 |
32,344 |
|
- |
|
128 Records found
|
|
Page 1 of 6 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.01 (0.68%) 
